displaying 1 - 10 records in total 11
    records per page




    Prevalence SERO and Risk Factors of Thrombotic MESHD Events on Patients with COVID-19: A Systematic Review and Meta-Analysis MESHD

    Authors: Xiaoming Xiong; Jianhua Chi; Qinglei Gao

    doi:10.21203/rs.3.rs-80187/v1 Date: 2020-09-18 Source: ResearchSquare

    BackgroundCoagulation abnormalities in COVID-19 patients accompanied with poor prognosis.This study aimed to determine the prevalence SERO and risk factors of thrombotic MESHD events on COVID-19 patients.MethodsWe systematically reviewed all the studies about thrombotic MESHD events on COVID-19 patients in PubMed, Embase, Web of Science, MedRxiv, bioRxiv, from Dec 1st, 2019 to July 5, 2020. The weighted mean difference (MD) or odds ratio (OR) or relative risk (RR) with 95% confidence intervals (CI) for clinical data in COVID-19 patients with or without thrombotic MESHD events was calculated. Results12 articles contained 1083 patients were included for meta-analysis. The prevalence SERO of thrombosis MESHD was 22% (95% CI 0.08-0.40) in COVID-19 patients and increased to 43% (95% CI 0.29-0.65) after admission to the intensive care unit (ICU). Compared with non-thrombotic MESHD patients, thrombotic MESHD patients had higher levels of D-dimer (MD=2.79, 95% CI 2.27–3.31), lactate dehydrogenase (LDH) (MD=112.71, 95% CI 62.40–163.02), and white blood SERO cells (WBC) (MD=1.14, 95% CI 0.47–1.81) while decreased lymphocytes (MD= -0.20, 95% CI -0.38 – -0.02). Age TRANS, platelet counts, and male TRANS sex tended to be risks while diabetes MESHD tended to be a protection for thrombosis MESHD for COVID-19 patients, although no statistical difference was achieved. Finally, patients with thrombosis MESHD were at a higher risk of death MESHD (OR=2.39, 95% CI 1.36–4.20).ConclusionsPrevalence of thrombosis MESHD in COVID-19 patients was high, especially in ICU, though pharmacologic thromboembolism HP thromboembolism MESHD prophylaxis was applied. Therefore, higher levels of D-dimer, LDH, WBC, and decreased lymphocytes needed to be paid close attention to in patients with COVID-19.

    CLINICAL COURSE, RISK FACTORS FOR TRANSFER TO ICU AND MORTALITY IN MESHD PATIENTS WITH COVID-19 AFFECTED BY ACUTE RESPIRATORY FAILURE HP REFERRED TO A RESPIRATORY INTERMEDIATATE CARE UNIT.

    Authors: Enrico Buonamico; Vitaliano Nicola Quaranta; Esterina Boniello; Michela Dimitri; Marco Majorano; Luciana Labate; Paola Pierucci; Federica Barratta; Giovanna Elisiana Carpagnano; Onofrio Resta; Anil Hormis; Neil Todd; Antoanela Colda; Ian Reckless; Tim Brooks; Andre Charlett; Matthew Hickman; Isabel Oliver; David Wyllie

    doi:10.1101/2020.08.19.20178350 Date: 2020-08-22 Source: medRxiv

    Introduction There are no clear guidelines as yet for the selection of patients affected by COVID-19 who can be treated in intermediate RICU, neither shared criteria for their intubation and transfer in ICU. In the present study we described the clinical course and risk factors for transfer to ICU and mortality of SARS-Cov-2 positive patients affected by acute respiratory failure HP respiratory failure MESHD, hospitalized in a Respiratory Intermediate Care Unit in the south of Italy. Methods In this retrospective, observational single centre study we evaluated 96 laboratory confirmed COVID-19 patients affected by acute respiratory failure MESHD respiratory failure HP ( ARF MESHD). We compared demographic data, laboratory data and clinical outcomes between deceased and survived patients, aiming to identify risk factors for transfer to ICU and mortality, and possible gender TRANS-related differences. Results Of 96 patients, 51 (53.1%) survived and 45 (46.9 %) died. Among those who died, 23 (51.1%) deceased in RICU. Twenty-nine (30.2%) were transferred to ICU, of whom 22 (75.9%) died in ICU. Patients affected by COPD MESHD have a higher mortality compared to patients without this comorbidity (p=0.002). Lower baseline P/F ratio (p=0,014) and neurologic comorbidities (p=0,008) emerged as risk factors for death MESHD. Male TRANS were younger than female TRANS patients (66 vs 80 y.o.; p=0.042). In female TRANS patients, lower peripheral blood SERO lymphocyte count (p=0.007) is a risk factor for death MESHD, characteristic gender TRANS-related in our sample. Female TRANS sex was a protective parameter against transfer to ICU (p=0,036) and P/F ratio was not a significant predictor of transfer to ICU (p=0,227). Only higher baseline CRP (p=0,034) has shown a predictive role for transfer to ICU in our sample. Patients deceased after a transfer to ICU had younger age TRANS (p=0,000), lower median comorbidity number (p=0,000), lower D-dimer (p=0,029) and lower prevalence SERO of female TRANS sex (p=0,029). Discussion Mortality in our study was similar to that found in other studies involving patients in non-invasive ventilation. In our study older age TRANS and comorbidities play as predictors of death in COVID-19 patients. COPD MESHD, despite presenting low prevalence SERO, is a risk factor for death MESHD, both in men and women. In female TRANS patients chronic ischemic heart disease MESHD and congestive heart failure HP congestive heart failure MESHD are death MESHD predictors. High CRP and lymphopenia HP lymphopenia MESHD, linked to inflammatory status, are predictors of transfer to ICU. Patients transferred to ICU higher mortality than the others, and patients who die in ICU are mostly men, younger and have less comorbidities. Baseline P/F ratio is not a good predictor of transfer to ICU, while in our sample is a sensible predictor of death MESHD. More studies need to be performed on COVID-19 patients, in the urgency of COVID-19 pandemic persistence.

    High SARS-CoV-2 seroprevalence SERO in Health Care Workers but relatively low numbers of deaths in urban Malawi

    Authors: Marah Grace Chibwana; Khuzwayo Chidiwa Jere; Jonathan Mandolo; Vincent Katunga-Phiri; Dumizulu Tembo; Ndaona Mitole; Samantha Musasa; Simon Sichone; Agness Lakudzala; Lusako Sibale; Prisca Matambo; Innocent Kadwala; Rachel Louise Byrne; Alice Mbewe; Marc Y.R. Henrion; Ben Morton; Chimota Phiri; Jane Mallewa; Henry C Mwandumba; Emily R Adams; Stephen B Gordon; Kondwani Charles Jambo

    doi:10.1101/2020.07.30.20164970 Date: 2020-08-01 Source: medRxiv

    Background In low-income countries, like Malawi, important public health measures including social distancing or a lockdown, have been challenging to implement owing to socioeconomic constraints, leading to predictions that the COVID-19 pandemic would progress rapidly. However, due to limited capacity to test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD, there are no reliable estimates of the true burden of infection MESHD and death MESHD. We, therefore, conducted a SARS-CoV-2 serosurvey amongst health care workers (HCW) in Blantyre city to estimate the cumulative incidence of SARS-CoV-2 infection MESHD in urban Malawi. Methods Five hundred otherwise asymptomatic TRANS HCWs were recruited from Blantyre City (Malawi) from 22nd May 2020 to 19th June 2020 and serum samples SERO were collected all participants. A commercial ELISA SERO was used to measure SARS-CoV-2 IgG antibodies SERO in serum SERO. We run local negative samples (2018 - 2019) to verify the specificity of the assay. To estimate the seroprevalence SERO of SARS CoV-2 antibodies SERO, we adjusted the proportion of positive results based on local specificity of the assay. Results Eighty-four participants tested positive for SARS-CoV-2 antibodies SERO. The HCW with a positive SARS-CoV-2 antibody SERO result came from different parts of the city. The adjusted seroprevalence SERO of SARS-CoV-2 antibodies SERO was 12.3% [CI 9.0-15.7]. Using age TRANS-stratified infection MESHD fatality estimates reported from elsewhere, we found that at the observed adjusted seroprevalence SERO, the number of predicted deaths MESHD was 8 times the number of reported deaths MESHD. Conclusion The high seroprevalence SERO of SARS-CoV-2 antibodies SERO among HCW and the discrepancy in the predicted versus reported deaths MESHD, suggests that there was early exposure but slow progression of COVID-19 epidemic in urban Malawi. This highlights the urgent need for development of locally parameterised mathematical models to more accurately predict the trajectory of the epidemic in sub-Saharan Africa for better evidence-based policy decisions and public health response planning.

    Seroprevalence SERO of anti-SARS-CoV-2 IgG antibodies SERO in Kenyan blood SERO donors

    Authors: Sophie Uyoga; Ifedayo M.O. Adetifa; Henry K. Karanja; James Nyagwange; James Tuju; Perpetual Wanjiku; Rashid Aman; Mercy Mwangangi; Patrick Amoth; Kadondi Kasera; Wangari Ng'ang'a; Charles Rombo; Christine K. Yegon; Khamisi Kithi; Elizabeth Odhiambo; Thomas Rotich; Irene Orgut; Sammy Kihara; Mark Otiende; Christian Bottomley; Zonia N. Mupe; Eunice W. Kagucia; Katherine Gallagher; Anthony Etyang; Shirine Voller; John Gitonga; Daisy Mugo; Charles N. Agoti; Edward Otieno; Leonard Ndwiga; Teresa Lambe; Daniel Wright; Edwine Barasa; Benjamin Tsofa; Philip Bejon; Lynette I. Ochola-Oyier; Ambrose Agweyu; J. Anthony G. Scott; George M Warimwe

    doi:10.1101/2020.07.27.20162693 Date: 2020-07-29 Source: medRxiv

    Background There are no data on SARS-CoV-2 seroprevalence SERO in Africa though the COVID-19 epidemic curve and reported mortality differ from patterns seen elsewhere. We estimated the anti- SARS-CoV-2 antibody SERO prevalence SERO among blood SERO donors in Kenya. Methods We measured anti-SARS-CoV-2 spike IgG prevalence SERO by ELISA SERO on residual blood SERO donor samples obtained between April 30 and June 16, 2020. Assay sensitivity SERO and specificity were 83% (95% CI 59, 96%) and 99.0% (95% CI 98.1, 99.5%), respectively. National seroprevalence SERO was estimated using Bayesian multilevel regression and post-stratification to account for non-random sampling with respect to age TRANS, sex and region, adjusted for assay performance SERO. Results Complete data were available for 3098 of 3174 donors, aged TRANS 15-64 years. By comparison with the Kenyan population, the sample over-represented males TRANS (82% versus 49%), adults TRANS aged TRANS 25-34 years (40% versus 27%) and residents of coastal Counties (49% versus 9%). Crude overall seroprevalence SERO was 5.6% (174/3098). Population-weighted, test-adjusted national seroprevalence SERO was 5.2% (95% CI 3.7, 7.1%). Seroprevalence SERO was highest in the 3 largest urban Counties; Mombasa (9.3% [95% CI 6.4, 13.2%)], Nairobi (8.5% [95% CI 4.9, 13.5%]) and Kisumu (6.5% [95% CI 3.3, 11.2%]). Conclusions We estimate that 1 in 20 adults TRANS in Kenya had SARS-CoV-2 antibodies SERO during the study period. By the median date of our survey, only 2093 COVID-19 cases and 71 deaths had been reported through the national screening system. This contrasts, by several orders of magnitude, with the numbers of cases and deaths MESHD reported in parts of Europe and America when seroprevalence SERO was similar.

    Clinical characteristics and Mortality risk factors among COVID-19 patients in Qom–Iran; The results of a Retrospective Cohort study

    Authors: Ahmad Hormati; SeyedYaser Foroghi Ghomi; masoudreza sohrabi; Ali Gholami; Saeede Jafari; Amir Jabbari; Reza AminNejad; Javad Khodadadi; Mansoureh shakeri; Alireza ShahHamzeh; Mahbobeh Afifian; Zohre Azad; Sajjad Ahmadpour; MohammadHadi Karbalai; MohammadReza Babaei; Parisa Karimzadeh; SeyedKamal Esshagh Hosseini

    doi:10.21203/rs.3.rs-42497/v1 Date: 2020-07-13 Source: ResearchSquare

    Background & AimCoronavirus 2019 (COVID-19) outbreak in the Middle East was initially reported in Qom-Iran. Clinical and epidemiologic and mortality risk factors details have not been already fully explained.MethodIn a retrospective study, the hospitalized adult TRANS patients with laboratory diagnosed COVID-19 between February 25 to March 20, 2020 were enrolled. A checklist including demographic, clinical, laboratorial, imaging, and treatment data was completed for each of the participant. The data were extracted from electronic medical records. In case of lack of information, a member of the research team contacted them via phone. All the dead patients and the first one hundred survived patients with these criteria were enrolled in the study. Outcome defined as death MESHD or discharge of patients.ResultsOf admitted patients, 200 patients who had been discharged or died were involved in this study. The majority of them were male TRANS (56%). The mean age TRANS of all patients was 62.63 ± 14.9. Co-morbidity was reported in 124 (62%) patients in which hypertension HP hypertension MESHD was the most common. The most frequent clinical presentations were dyspnea HP dyspnea MESHD in 169 (84.5%), cough HP cough MESHD in 150 (75%), and fatigue HP fatigue MESHD/weakness in 123 (61.5%) patients. The main complications were respiratory failure HP respiratory failure MESHD and acute respiratory distress syndrome MESHD respiratory distress HP syndrome with prevalence SERO of 143 (71.5%) and 105 (52.5%), accordingly. Multiple logistic models showed that decline of hemoglobin level (OR = 10.09), neutrophilia HP (OR = 3.48), high blood SERO urea nitrogen (OR = 4.29,), SpO2 ≤ 90% (OR = 3.38), and presence of patchy consolidation (OR = 6.81) were associated with poor outcome.ConclusionCOVID-19 disease has multiple aspects. CT scan findings, complete blood SERO count with differential, high blood SERO urea nitrogen and SpO2 are related to mortality. Hence needs to pay serious attention during admitting and surveillance, particularly among elderly TRANS patients and who with preexisting morbidities.

    Antibody Testing SERO Documents the Silent Spread of SARS-CoV-2in New York Prior to the First Reported Case

    Authors: Kathrine Meyers; Lihong Liu; Wen-Hsuan Lin; Yang Luo; Michael Yin; Yumeng Wu; Sandeep Wontakal; Alex Rai; Francesca La Carpia; Sebastian Fernando; Mitra Dowlatshahi; Elad Elkayam; Ankur Garg; Leemor Joshua-Tor; John Wolk; Barbara Alpert; Marie-Laure Romney; Brianna Costabile; Edoardo Gelardi; Francesca Vallese; Oliver Clarke; Filippo Mancia; Anne-Catrin Uhlemann; Magdalena Sobieszczyk; Alan Perelson; Yaoxing Huang; Eldad Hod; David Ho

    doi:10.21203/rs.3.rs-39880/v1 Date: 2020-07-02 Source: ResearchSquare

    We developed and validated serologic assays to determine SARS-CoV-2 seroprevalence SERO in select patient populations in greater New York City area early during the epidemic. We tested “discarded” serum samples SERO from February 24 to March 29 for antibodies SERO against SARS-CoV-2 spike trimer and nucleocapsid protein. Using known durations for antibody SERO development, incubation period TRANS, serial interval TRANS, and reproductive ratio for this pandemic, we determined that introduction of SARS-CoV-2 into New York likely occurred between January 23 and February 4, 2020. SARS-CoV-2 spread silently for 4–5 weeks before the first community acquired infection MESHD was reported. A novel coronavirus emerged in December 2019 in Wuhan, China1,2 and devasted Hubei Province in early 2020 before spreading to every province within China and nearly every country in the world3. This pathogen, now termed severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), has caused a global pandemic, with ~ 10 million cases and over 500,000 deaths MESHD reported through June 30, 20203. The first case of SARS-CoV-2 infection MESHD in the United States was identified on January 19, 2020 in a man who returned to the State of Washington from Wuhan4. In the ensuing months, the U.S. has become a hotspot of the pandemic, presently accounting for almost one third of the total caseload and over one fourth of the deaths3. The first confirmed case TRANS in New York was reported on March 1 in a traveler recently returned from Iran. The first community-acquired SARS-CoV-2 infection MESHD was diagnosed on March 3 in a 50-year-old male TRANS who lived in New Rochelle and worked in New York City (https://www1.nyc.gov/site/doh/covid/covid-19-data-archive.page.) In the ensuing 18 weeks, New York City has suffered a peak daily infection number of ~ 4,500 (Fig. 1a) and a cumulative caseload of ~ 400,000 to date. The time period when SARS-CoV-2 gained entry into this epicenter of the pandemic remains unclear.

    Identifying novel factors associated with COVID-19 transmission TRANS and fatality using the machine learning approach

    Authors: Mengyuan Li; Zhilan Zhang; Wenxiu Cao; Yijing Liu; Beibei Du; Canping Chen; Qian Liu; Md. Nazim Uddin; Shanmei Jiang; Cai Chen; Yue Zhang; Xiaosheng Wang

    doi:10.1101/2020.06.10.20127472 Date: 2020-06-12 Source: medRxiv

    The COVID-19 virus has infected millions of people and resulted in hundreds of thousands of deaths worldwide. By using the logistic regression model, we identified novel critical factors associated with COVID19 cases, death MESHD, and case fatality rates in 154 countries and in the 50 U.S. states. Among numerous factors associated with COVID-19 risk, we found that the unitary state system was counter-intuitively positively associated with increased COVID-19 cases and deaths. Blood SERO type B was a protective factor for COVID-19 risk, while blood SERO type A was a risk factor. The prevalence SERO of HIV, influenza and pneumonia HP pneumonia MESHD, and chronic lower respiratory diseases MESHD was associated with reduced COVID-19 risk. Obesity HP Obesity MESHD and the condition of unimproved water sources were associated with increased COVID-19 risk. Other factors included temperature, humidity, social distancing, smoking, and vitamin D intake. Our comprehensive identification of the factors affecting COVID-19 transmission TRANS and fatality may provide new insights into the COVID-19 pandemic and advise effective strategies for preventing and migrating COVID-19 spread.

    The Cardiac Injury MESHD in Hospitalized Patients with Severe COVID-19 in Wuhan, China

    Authors: Sen Lu; Hongli He; Rong an Liu; Yaqiu Wu; Lei Deng; Pin Wang; Weiwei Huang; Yong Peng; Hongwen Xiao; Gang Li; Xiaobo Huang

    doi:10.21203/rs.3.rs-29681/v1 Date: 2020-05-19 Source: ResearchSquare

    Background: The Coronavirus disease 2019 (COVID-19) has caused a global pandemic since December 2019, while the date on the relationship between cardiac injury MESHD and mortality in patients with COVID-19 is limited.Methods: All consecutive lab-confirmed critically ill COVID-19 patients in intensive care unit of Wuhan Red Cross Hospital from December 30, 2019 to March 18, 2020, were enrolled. Data of patients were collected. The prevalence SERO of cardiac injury MESHD and its association with in-hospital mortality was analyzed.Results: Among the 50 ICU patients, 36 patients (72.0%) were complicated with cardiac injury MESHD and 14 patients (28.0%) without cardiac injury MESHD. Patients with cardiac injury MESHD had higher white blood SERO cell counts, values of d-dimer, levels of lactate concentration, APACHE II score and lower PaO2/FiO2 at the time of admission than those without cardiac injury MESHD. The in-hospital case fatality ratio was higher in the cardiac injury MESHD than non- cardiac injury MESHD group (75.0% vs 21.4%;p=0.002).Multivariable-adjusted logistic proportional hazard regression analysis showed that a significantly higher risk of death MESHD in patients with cardiac injury MESHD than those without cardiac injury MESHD (OR, 5.876; 95% CI, 1.039–33.228).Conclusions: Cardiac injury MESHD is a common compilation and associated with higher risk of in-hospital death MESHD in patients with severe COVID-19. 

    Clinical Characteristics and Short-Term Outcomes of Severe Patients with COVID-19 in Wuhan, China

    Authors: Xiaobo Feng Sr.; Peiyun Li; Liang Ma; Hang Liang; Jie Lei; Wenqiang Li; Kun Wang; Yu Song; Shuai Li; Wei Yang; Cao Yang

    doi:10.1101/2020.04.24.20078063 Date: 2020-04-29 Source: medRxiv

    Objective. A novel pneumonia HP pneumonia MESHD (COVID-19) which is sweeping the globe was started in December, 2019, in Wuhan, China. Most deaths MESHD occurred in severe and critically cases, but information on prognostic risk factors for severe ill patients is incomplete. Further research is urgently needed to guide clinicians, so we prospectively evaluate the clinical outcomes of 114 severe ill patients with COVID-19 for short-term in the Union Hospital in Wuhan, China. Methods. In this single-centered, prospective and observational study, we enrolled 114 severe ill patients with confirmed COVID-19 from Jan 23, 2020 to February 22, 2020. Epidemiological, demographic and laboratory information were collected at baseline, data on treatment and outcome were collected until the day of death MESHD or discharge or for the first 28 days after severe ill diagnosis, whichever was shorter. Univariate and multivariate Cox proportional hazard models were used to determine hazard ratios (HRs) and 95% confidence intervals (CIs) of poor outcome. Results. Among enrolled 114 patients, 94 (82.5%) had good outcome while 20 (17.5%) had poor outcome. No significant differences were showed in age TRANS, gender TRANS and the prevalence SERO of coexisting disorders between outcome groups. Results of multivariate Cox analyses indicated that higher levels of oxygen saturation (HR, 0.123; 95% CI, 0.041-0.369), albumin (HR, 0.060; 95% CI, 0.008-0.460) and arterial partial pressure of oxygen (HR, 0.321; 95% CI, 0.106-0.973) were associated with decreased risk of developing poor outcome within 28 days. In the other hand, higher levels of leucocytes (HR, 5.575; 95% CI, 2.080-14.943), neutrophils (HR, 2.566; 95% CI, 1.022-6.443), total bilirubin (HR, 6.171; 95% CI, 2.458-15.496), globulin (HR, 2.526; 95% CI, 1.027-6.211), blood SERO urea nitrogen (HR, 5.640; 95% CI, 2.193-14.509), creatine kinase-MB (HR, 3.032; 95% CI, 1.203-7.644), lactate dehydrogenase (HR, 4.607; 95% CI, 1.057-20.090), hypersensitive MESHD cardiac troponin I (HR, 5.023; 95% CI, 1.921-13.136), lactate concentration (HR,15.721; 95% CI, 2.099-117.777), Interleukin-10 (HR, 3.551; 95% CI, 1.280-9.857) and C-reactive protein (HR, 5.275; 95% CI, 1.517-18.344) were associated with increased risk of poor outcome development. We also found that traditional Chinese medicine can significantly improve the patient's condition, which is conducive to the transformation from severe to mild. Conclusion. In summary, we firstly reported this single-centered, prospective and observational study for short-term outcome in severe patients with COVID-19. We found that cytokine storm and uncontrolled inflammation MESHD responses, liver, kidney, cardiac dysfunction MESHD may play important roles in final outcome of severe ill patients with COVID-19. Our study will provide clinicians to be benefit to rapidly estimate the likelihood risk of short-term poor outcome for severe patients.

    Blood SERO glucose is a representative of the clustered indicators of multi-organ injury for predicting mortality of COVID-19 in Wuhan, China

    Authors: Jin-Kui Yang; Jian-Min Jin; Shi Liu; Peng Bai; Wei He; Fei Wu; Xiao-Fang Liu; Zhong-Lin Chai; De-Min Han

    doi:10.1101/2020.04.08.20058040 Date: 2020-04-11 Source: medRxiv

    Background Concomitance with diabetes MESHD is associated with high mortality in critical conditions. Patients with previous diabetes MESHD are more vulnerable to COVID-19. However, new-onset COVID-19-related diabetes MESHD (CRD) and its relevance have scarcely been reported. This study investigates new-onset CRD and its correlation with poor outcomes or death MESHD in patients with COVID-19. Methods We performed a single center, retrospective case series study in 120 patients with laboratory confirmed COVID-19 at a university hospital. Fasting blood SERO glucose (FBG) [≥]7.0 mmol/L for two times during hospitalization and without a history of diabetes MESHD were defined as CRD. The Critical status was defined as admitted to intensive care unit (ICU) or death MESHD. Results After excluding patients with a history of diabetes MESHD, chronic heart, kidney, and liver disease MESHD, 69 patients with COVID-19 were included in the final analysis. Of the 69 patients, 23 were Moderate, 20 were Severe, and 26 were Critical (including 16 deceased patients). The prevalence SERO of CRD in Critical and Moderate+Severe patients was 53.85% and 13.95%, respectively. Kaplan-Meier survival analysis revealed a significantly higher mortality rate in patients with CRD (P=0.0019). Multivariable analysis indicated that CRD was an independent predictor for death MESHD (HR = 3.75, 95% CI 1.26-11.15). Cluster analysis suggested that indicators for multi-organ injury were interdependent, and more proximities of FBG with indicators for multi-organ injury MESHD was present. Conclusion Our results suggest that new onset COVID-19-related diabetes MESHD is an indicator of multi-organ injury MESHD and predictor for poor outcomes and death MESHD in COVID-19 patients. As it is easy to perform for clinical practices and even self-monitoring, glucose testing will be much helpful for predicting poor outcomes to facilitate appropriate intensive care in patients with COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.